EUVIMEDEUVIMED entdecken
Open Access

sPLA 2 -reacted extracellular vesicles (SPLEVs) as a therapeutic modality for cytokine storm syndromes

Shunya Nakayama iD, Akane Kanamori iD, Takeshi Kamakura iD, Kosuke Kamiya iD, Kai Kudo iD, Ryo Yanagiya iD, Takanobu Shimizu iD, Yoshimi Miki iD, Yuki Nagasaki iD, Masaya Araki iD, Koichiro Tateishi iD, Yoko Ito iD und 9 weitere

Science Advances · 2026

DOI: 10.1126/sciadv.adr9135 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Science Advances, 2026. Verfasst von Shunya Nakayama und 20 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology and Oncology, Tokai University School of Medicine, Isehara, Kanagawa, Japan. Hauptthemen laut MEDLINE: Extracellular Vesicles, Cytokine Release Syndrome, Phospholipases A2, Secretory. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 97 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Because cytokine storm syndromes such as sepsis, acute respiratory distress syndrome (ARDS), and coagulopathy, including those seen in COVID-19, are fatal, development of highly effective therapeutics is urgently needed. Recent evidence suggests that the hydrolysis of phospholipids in extracellular vesicles (EVs) by secreted phospholipase A 2 (sPLA 2 ) can augment the ability of EVs to modulate inflammation, allergy, and cancer. We aimed to apply this phenomenon technically using “sPLA 2 -reacted EVs (SPLEVs),” which showed high therapeutic efficacies against ARDS and other diseases. Mechanistically, SPLEVs bind to type II alveolar epithelial cells, increase membrane fluidity by reorganizing phospholipid building blocks with more polyunsaturated fatty acids through the sterol regulatory element–binding protein 1 pathway, and elicit “lipid counterstorm” by increasing tissue-protective lipid mediators. The potent therapeutic effects of SPLEVs depend partly on sPLA 2 -driven generation of lysophosphatidylglycerol. Thus, SPLEVs are expected to be an effective therapeutic tool for treatment of broad ranges of inflammatory diseases including COVID-19 and other new pandemic diseases.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Extracellular VesiclesCytokine Release SyndromePhospholipases A2, SecretoryHumansCOVID-19AnimalsSARS-CoV-2PhospholipidsMembrane Fluidity

Substanzen

Phospholipases A2, SecretoryPhospholipids

Autor:innen und Institutionen

  • Department of Hematology and Oncology, Tokai University School of Medicine, Isehara, Kanagawa, Japan.
  • Department of Veterinary Medicine, College of Bioresource Sciences, Nihon University, Fujisawa, Kanagawa, Japan.
  • Department of Molecular Life Sciences, Tokai University School of Medicine, Isehara, Kanagawa, Japan.
  • Department of Regulation of Infectious Cancer, Division of Cellular and Molecular Biology, Research Institute for Microbial Diseases, The University of Osaka, Suita, Osaka, Japan.
  • Department of Innovative Medical Science, Tokai University School of Medicine, Isehara, Kanagawa, Japan.
  • Laboratory of Microenvironmental Metabolic Health Sciences, Center for Disease Biology and Integrative Medicine, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.

ORCID-Profile: Shunya Nakayama, Akane Kanamori, Takeshi Kamakura, Kosuke Kamiya, Kai Kudo, Ryo Yanagiya, Takanobu Shimizu, Yoshimi Miki, Yuki Nagasaki, Masaya Araki, Koichiro Tateishi, Yoko Ito, Yoshiki Shiraishi, Yasushi Nakamoto, Hiroyuki Hosokawa, Yumi Matsuzaki, Hitoshi Shimano, Koichiro Asano, Norio Yamamoto, Makoto Murakami

Zitieren

APA

Nakayama, S., Kanamori, A., Kamakura, T., Kamiya, K., Kudo, K., Yanagiya, R., Shimizu, T., Miki, Y., Nagasaki, Y., Araki, M., Tateishi, K., Ito, Y., Shiraishi, Y., Nakamoto, Y., Hosokawa, H., Matsuzaki, Y., Shimano, H., Asano, K., Yamamoto, N., …, & Kotani, A. (2026). sPLA 2 -reacted extracellular vesicles (SPLEVs) as a therapeutic modality for cytokine storm syndromes. Science Advances. https://doi.org/10.1126/sciadv.adr9135

Vancouver

Nakayama S, Kanamori A, Kamakura T, Kamiya K, Kudo K, Yanagiya R, et al. sPLA 2 -reacted extracellular vesicles (SPLEVs) as a therapeutic modality for cytokine storm syndromes. Science Advances. 2026. doi:10.1126/sciadv.adr9135

BibTeX
@article{Nakayama2026,
  author = {Nakayama, Shunya and Kanamori, Akane and Kamakura, Takeshi and Kamiya, Kosuke and Kudo, Kai and Yanagiya, Ryo and Shimizu, Takanobu and Miki, Yoshimi and Nagasaki, Yuki and Araki, Masaya and Tateishi, Koichiro and Ito, Yoko and Shiraishi, Yoshiki and Nakamoto, Yasushi and Hosokawa, Hiroyuki and Matsuzaki, Yumi and Shimano, Hitoshi and Asano, Koichiro and Yamamoto, Norio and Murakami, Makoto and Kotani, Ai},
  title = {sPLA 2 -reacted extracellular vesicles (SPLEVs) as a therapeutic modality for cytokine storm syndromes},
  journal = {Science Advances},
  year = {2026},
  doi = {10.1126/sciadv.adr9135}
}
Kostenlos starten →